Selected article for: "disease fast spread and fast spread"
Author: Calabrò, Luana; Rossi, Giulia; Covre, Alessia; Morra, Aldo; Maio, Michele
Title: COVID and Lung Cancer
  • Cord-id: ss010jjn
  • Document date: 2021_10_22
    • ID: ss010jjn
    Snippet: PURPOSE OF REVIEW: Since the past year, the fast spread of coronavirus disease 2019 (COVID-19) has represented a global health threat, especially for cancer patients, that has required an urgent reorganization of clinical activities. Here, we will critically revise the profound impact that the pandemic has generated in lung cancer patients, as well the most significant challenges that oncologists have to face to maintain the highest possible standards in the management of lung cancer patients in
    Document: PURPOSE OF REVIEW: Since the past year, the fast spread of coronavirus disease 2019 (COVID-19) has represented a global health threat, especially for cancer patients, that has required an urgent reorganization of clinical activities. Here, we will critically revise the profound impact that the pandemic has generated in lung cancer patients, as well the most significant challenges that oncologists have to face to maintain the highest possible standards in the management of lung cancer patients in the pandemic era. RECENT FINDINGS: Evidences suggested a higher susceptibility and mortality of lung cancer patients due to COVID-19. The hard management of this patient population has been also due to the potential cross interference of anti-tumor drugs on SARS-Cov-2 infection and to the differential diagnosis between COVID-19 pneumonitis and drug-related pneumonitis. SUMMARY: COVID-19 pandemic has generated a profound reshaping of oncological activities and the development of recommendations by the oncology scientific community to prioritize anti-tumor treatments for lung cancer patients.

    Search related documents:
    Co phrase search for related documents
    • active therapy and adaptive immune response: 1
    • active therapy and locally advanced: 1
    • active therapy and long course: 1
    • active therapy and lung cancer: 1, 2, 3, 4, 5, 6, 7
    • acute interstitial pneumonitis and locally advanced: 1
    • acute interstitial pneumonitis and lung cancer: 1, 2
    • acute viral infection and adaptive immune response: 1, 2, 3, 4
    • acute viral infection and lung alveolar: 1, 2, 3
    • acute viral infection and lung cancer: 1
    • adaptive immune response and lung cancer: 1
    • locally advanced and long course: 1, 2, 3, 4, 5
    • locally advanced and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • long course and lung alveolar: 1